Skip to content

2026

  • 4 min read

Q1 2026 Platform Update: Advancing Viral Surveillance, Sequencing Flexibility, AMR Prediction, and EPI2ME Integration

The landscape of clinical microbiology and public health is evolving faster than ever. At BugSeq, we are continuously enhancing our platform to ensure laboratories have the most advanced, accurate, and rapid bioinformatics tools at their disposal. In the first quarter of 2026, we focused our efforts on four major areas: deepening our viral surveillance capabilities, optimizing our pipelines for the rapid turnaround of the new Illumina MiSeq i100, expanding our expert-curated Antimicrobial Resistance (AMR) databases, and seamlessly integrating with Oxford Nanopore’s EPI2ME Desktop environment.

  • 6 min read

BugID: A machine learning enabled tool to implement evidence-based reporting thresholds specific to your NGS assay

Pathogen agnostic diagnostic assays, driven by metagenomic next-generation sequencing (mNGS), enable diagnosis and surveillance of pathogens unlike any other technology. However, a lack of bioinformatic frameworks and evidence to guide reporting thresholds has made the technology too complex for most labs. BugSeq’s latest innovation, BugID, brings intuitive, evidence-based thresholds within reach for your metagenomic assay.